HC Wainwright & Co. Reiterates Buy on Celldex Therapeutics, Maintains $80 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Celldex Therapeutics (NASDAQ:CLDX) and maintained a price target of $80.
May 15, 2024 | 2:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Celldex Therapeutics and maintained a price target of $80.
The reiteration of a Buy rating and the maintenance of a high price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100